Ziarco appoints David Brinkley to the Board of Directors

The firm focuses on developing treatments for inflammatory and allergic diseases

Ziarco, a UK biopharmaceutical company focusing on inflammatory and allergic diseases, has appointed David Brinkley to the Board of Directors to provide input on the company’s corporate, R&D strategy and business plans.

Brinkley was recently Head of Business Development at Theravance and had previously served as Senior Vice President, Commercial Development at the firm from September 2000 to December 2007, when he left to start a consulting practice.

From 1996 to 2000 Brinkley was Worldwide Team Leader for Viagra at Pfizer. He joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Brinkley also held various management positions with SmithKline from 1983 to 1995.

Ziarco is based in Canterbury, Kent. It was set up last year by Mike Yeadon formerly Chief Scientist in the allergy and respiratory research unit of Pfizer in Sandwich, Kent.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now